These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3780832)

  • 21. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
    Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
    Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibiotic treatment of lung disease in cystic fibrosis].
    Biasini GC; Pistocchi E; Miano A
    Pediatr Med Chir; 1983; 5(4):157-60. PubMed ID: 6647075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients.
    Schaad UB; Guenin K; Straehl P
    Rev Infect Dis; 1986; 8 Suppl 5():S512-7. PubMed ID: 3025998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple-dose amikacin kinetics in pediatric oncology patients.
    Kramer WG; Cleary T; Frankel LS; Kohl S; Pickering LK
    Clin Pharmacol Ther; 1979 Nov; 26(5):635-40. PubMed ID: 498705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
    Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients.
    Bosso JA; Townsend PL; Herbst JJ; Matsen JM
    Antimicrob Agents Chemother; 1985 Dec; 28(6):829-31. PubMed ID: 4083865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bronchial secretion levels of amikacin.
    Dull WL; Alexander MR; Kasik JE
    Antimicrob Agents Chemother; 1979 Dec; 16(6):767-71. PubMed ID: 533258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis.
    Goldfarb J; Wormser GP; Inchiosa MA; Guideri G; Diaz M; Gandhi R; Goltzman C; Mascia AV
    J Clin Pharmacol; 1986 Mar; 26(3):222-6. PubMed ID: 2937812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T; Solberg R
    Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):685-7. PubMed ID: 3807469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled liposomal amikacin.
    Waters V; Ratjen F
    Expert Rev Respir Med; 2014 Aug; 8(4):401-9. PubMed ID: 24882271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.
    Devereux G; Steele S; Griffiths K; Devlin E; Fraser-Pitt D; Cotton S; Norrie J; Chrystyn H; O'Neil D
    Clin Drug Investig; 2016 Aug; 36(8):605-12. PubMed ID: 27153825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.
    Sultan E; Richard C; Pezzano M; Auzepy P; Singlas E
    Eur J Clin Pharmacol; 1988; 34(6):637-43. PubMed ID: 3169115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of a high dose of amikacin administered at extended intervals to neonatal foals.
    Magdesian KG; Wilson WD; Mihalyi J
    Am J Vet Res; 2004 Apr; 65(4):473-9. PubMed ID: 15077690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function.
    Lanao JM; Domínguez-Gil A; Tabernero JM; De Castro S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):171-5. PubMed ID: 447438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Kinetics of multiple-dose amikacin in the newborn infant].
    Olivesi A; Camboulives J; Charrel C; Unal D
    Ann Anesthesiol Fr; 1981; 22(2):212-8. PubMed ID: 6115610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.